1 / 3

2014 UK National Lipoprotein Apheresis Conference Friday 7 th March 2014, 09:00-1600

2014 UK National Lipoprotein Apheresis Conference Friday 7 th March 2014, 09:00-1600 Venue: Hilton Manchester Airport Hotel, Manchester Airport, Outwood Lane, Manchester, M90 4WP CPD accreditation: 5 CPD applied for. 0920-0930 Welcome: Dr Handrean Soran Session 1

yin
Download Presentation

2014 UK National Lipoprotein Apheresis Conference Friday 7 th March 2014, 09:00-1600

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2014 UK National Lipoprotein Apheresis Conference Friday 7th March 2014, 09:00-1600 Venue: Hilton Manchester Airport Hotel, Manchester Airport, Outwood Lane, Manchester, M90 4WP CPD accreditation: 5 CPD applied for

  2. 0920-0930 Welcome: Dr Handrean Soran Session 1 0930-1010 Underestimation of the importance of LDL-cholesterol lowering in cardiovascular disease prevention in current practice. Professor Paul Durrington, Professor of Medicine, University of Manchester, UK. 1010-1050 Lipoprotein (a) as a cardiovascular risk factor: review of evidence and therapeutic options. Dr Dermot Neely, Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Victoria Infirmary, Newcastle, UK. 1050-1120 Coffee and networking Session 2 1120-1200 HoFH; is it just double trouble? The role of the LDL-receptor in lipid metabolism and implications for therapeutic options. Dr Michael France, Consultant Chemical Pathologist, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 1200-1240 Lipoprotein Apheresis: who and how should we treat? Dr Dev Datta, University Hospital Cardiff, Cardiff, UK. 1240-1350 Lunch Session 3 1350-1430 Lomitapide as a therapeutic option for HoFH. Professor Claudia Stefanutti, Professor of Internal Medicine, Extracorporeal Therapeutic Techniques Unit - Lipid Clinic and Atherosclerosis Prevention Centre, Department of Molecular Medicine ‘Sapienza’ University of Rome, Italy 1430-1500 Future therapeutic options for patients with HoFH. Dr Handrean Soran, Consultant Physician and Endocrinologist, Central Manchester University Hospital, UK. 1500-1530 Managing HoFH in children; challenges and options. Dr Andrew Morris, Consultant Paediatrician, Central Manchester University Hospitals NHS Foundation Trust. 1530-1600 Case discussions. HoFH in children; pheresis as a therapeutic option. 1600 Close Sponsors Aegereon, AMGEN, AstraZeneca, Link Medical, Sanofi. Agenda University of Manchester The Centre for Endocrinology & Diabetes

  3. ATTENDANCE FORM 2014 UK National Lipoprotein Apheresis Conference Friday 7th March 2014, 09:30-1600 Manchester CPD accreditation: 5 CPD applied for YES, I am able to attend the meeting on Friday 7th March 2014 To reserve your place, please complete the form and return at your earliest convenience to Sister Ruth Eatough Email: Ruth.Eatough@cmft.nhs.uk Fax: 0161 276 4684 CORRESPONDENCE DETAILS Name: ……………………………………………………………………………………………………………………... GP Surgery/Hospital: .…….…………………………………………………………………………………………. Role/Position:…………………………………………………………………………………………………………… Address: ………………………………………………………………………………………………………………….. ……………………………………………………………………………………………………………………………….. ……………………………………………………………………………………………………………………………….. Postcode: ……………………………………………………………………………....................................... Contact Number: ……………………………………………………………………................................... Email Address: ………………………………………………………………………………………………………… Please state any dietary requirements: ……………………………………………………………………. Signature: ……………………………………………………………………………………………………………….. Date: …………………………………………………………………………………………………………………………

More Related